3.36  0 (0%)		06-28 18:07
Open: 3.36 High: 3.36 Volume: 0		Pre. Close: 3.36 Low: 3.36 Market Cap: 0(M)

Short term
Mid term
Targets	6-month :		1-year :
Resists	First :		Second :
Pivot price
Supports	First :		Second :
MAs	MA(5) :		MA(20) :
	MA(100) :		MA(250) :
MACD	MACD :		Signal :
%K %D	K(14,3) :		D(3) :
RSI	RSI(14):
52-week	High :		Low :

If tomorrow:	Open lower	Open higher
High:	-	-
Low:	-	-
Close:	-	-

Wed, 01 Oct 2025
Proximity To Patients Helps Unicycive Reduce Pill Burden - Clinical Leader

Thu, 21 Nov 2024
DEBBIE WASSERMAN SCHULTZ Trading Activity - Quiver Quantitative

Tue, 10 Oct 2023
Peter Morgan Kash Net Worth (2026) - GuruFocus

Thu, 15 Nov 2018
Akebia Therapeutics and Keryx Biopharmaceuticals Announce Chairperson for Combined Company - BioSpace

Mon, 26 Mar 2018
Keryx Has a Very Good Product, but Is Not Profitable - GuruFocus

Mon, 04 Dec 2017
Keryx Biopharmaceuticals (KERX) Announces FDA Approval of Auryxia Tablets as a Treatment for People with Iron Deficiency Anemia and Chronic Kidney Disease, Not on Dialysis; Shares Tumble - Yahoo Finance

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	(%)
Held by Institutions	(%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS
EPS Est Next Qtrly
EPS Est This Year
EPS Est Next Year
Book Value (p.s.)
Profit Margin	%
Operating Margin	%
Return on Assets (ttm)	%
Return on Equity (ttm)	%
Qtrly Rev. Growth	%
Gross Profit (p.s.)
Sales Per Share
EBITDA (p.s.)
Qtrly Earnings Growth	%
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio
PEG Ratio
Price to Book value
Price to Sales
Price to Cash Flow

Dividend
Forward Dividend
Dividend Yield	0%
Dividend Pay Date
Ex-Dividend Date